Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer
Trial Parameters
Brief Summary
To find the recommended dose of TROP2- CAR-NK given intraperitoneally (directly into the abdominal cavity) to patients with highgrade serous ovarian cancer that has not responded to previous treatment or is resistant to treatment.
Eligibility Criteria
Inclusion criteria: 1. Subjects must be 18 years or older. 2. Subjects must be willing and able to provide informed consent. 3. Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 4. A female participant is eligible to participate if at least one of the following conditions applies: 1. Not a woman of childbearing potential (WOCBP) as defined in Appendix 1 2. A WOCBP who agrees to follow the contraceptive guidelines in Appendix 1 during the treatment period and for at least 3 months after the last dose of study treatment. 5. Subjects must have measurable disease present as defined by modified RECIST v1.1 criterion, and have disease present in the peritoneal cavity or retroperitoneal lymph nodes. Disease outside the peritoneal cavity is allowed as long as metastases are present within the peritoneal cavity or retroperitoneum. 6. Subject tumors must demonstrate at least 1+ TROP2 expression by immunohistochemistry. 7. Subjects must be at least 3 we